Repare Therapeutics RPTX 深 沪
等待开盘 12-15 09:30:00 美东时间
2.14
0.000
0.00%
华盛通- 最 高2.18
- 今 开2.15
- 成交量 84.94万股
- 最 低 2.13
- 昨 收 2.14
- 总市值 9193.27万
- 52周最高 2.30
- 市盈率 静 --
- 换手率 1.98%
- 52周最低 0.89
- 委 比 67.03%
- 总股本 4295.92万
- 历史最高 46.44
- 量 比 1.26
- 振 幅 2.34%
- 历史最低 0.89
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers enGene Holdings (NASDAQ:ENGN) stock moved upwards by 3.5% to $7.12 dur...
11-19 05:06
Repare Therapeutics Announces Acquisition by XenoTherapeutics
An update from Repare Therapeutics ( ($RPTX) ) is now available. Repare Therape...
11-17 22:46
Repare Therapeutics Q3 EPS $0.08 Beats $(0.12) Estimate, Sales $11.620M Beat $7.500M Estimate
Repare Therapeutics (NASDAQ:RPTX) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.12) by 166.67 percent. This is a 109.88 percent increase over losses of $(0.81) per share
11-15 05:47
Repare Therapeutics Enters Agreement To Be Acquired By XenoTherapeutics, Xeno Acquisition For $1.82/Share In Cash
Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement")
11-15 05:46
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3
HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price target from $5 to $3.
10-27 21:34
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
RASTherapeutics宣布将于10月20日发布其合作伙伴上海杰优医药开发的RPT904在慢性自发性荨麻疹患者中进行的II期临床试验顶线数据，并举行网络研讨会，提供电话和网络接入方式。公司简介及联系方式随附。
10-19 12:00
Repare Therapeutics To Share Initial Topline Safety, Tolerability And Early Efficacy Data From Phase 1 LIONS Trial In Poster Presentation At AACR-NCI-EORTC International Conference 2025
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy data from the Phase 1
10-14 04:06
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
RAPT Therapeutics received FDA clearance to initiate a Phase 2b trial for RPT904, a long-acting anti-IgE antibody, targeting food allergies. The trial will compare dosing every 8 or 12 weeks. RAPT expects to start the trial by year-end and anticipates data from Jeyou's Phase 2 studies in chronic urticaria and asthma. RPT904 aims to inhibit IgE, with better pharmacokinetics than first-gen anti-IgE drugs.
09-29 09:00
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport Therapeutics announced that its management will participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025. The company, focused on developing precision medicines for neurological and psychiatric disorders, will host a fireside chat during the virtual event. Investors can access the webcast on the company’s website. Rapport’s RAP technology platform enables the creation of targeted sma...
09-11 20:05
